ISTA Pharmaceuticals Submits Investigational New Drug Application For Eye Drop For The Treatment Of Allergic ... (Medical News Today)
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), an ophthalmic pharmaceutical company, today announced it has submitted an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) for its eye drop formulation of bepotastine for the treatment of allergic conjunctivitis. ISTA intends to move bepotastine directly into Phase II/III clinical trials in the U.S. [click link ...

Pharmaceutical, Healthcare & Life Sciences (Mondaq)
12 December 2006 Article by Bryan C Diner, Anthony C Tridico PhD and John C. Stolpa, Ph.D.